MedTrace Logo

Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease

NCT01463215 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-02-15

No results posted yet for this study

Summary

Ambroxol is expected to improve the signs and symptoms of patients with Type I Gaucher Disease.

Conditions

  • Type I Gaucher Disease

Interventions

DRUG

Ambroxol

Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.

Sponsors & Collaborators

  • Exsar Corporation

    lead INDUSTRY

Principal Investigators

  • Robert Johnston · Exsar Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-12-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01463215 on ClinicalTrials.gov